Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about MNOV, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Ibudilast (MN-166) | Amyotrophic Lateral Sclerosis | Phase 2/3 · NCT04057898 | Active not recruiting |
| Bedoradrine | Asthma | Phase 2 · NCT00683449 | Terminated |
| Tipelukast (MN-001) | Diabetes Mellitus, Type 2 | Phase 2 · NCT05464784 | Active not recruiting |
| Bedoradrine Sulfate | Asthma | Phase 2 · NCT00838591 | Completed |
| MN-221 | Chronic Obstructive Pulmonary Disease | Phase 1 · NCT01013142 | Completed |
Also used in these trials (approved or third-party drugs, not MNOV's own candidates): Riluzole, Temozolomide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
MNOV holds $25.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.7M/quarter from operations, an estimated runway of 28.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
As of the date of this report, we believe we have working capital sufficient to fund operations at least through November 2027.10-Q, Aug 2026
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MNOV files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MNOV and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →